|

EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Also known as: MSLN/MUC1 Dual-CAR NK, Dual-target CAR-NK (MSLN/MUC1)

Pipeline

Phase 1/2: 2

Top Sponsors

  • Beijing Biotech2

Indications

  • Pancreatic Ductal Adenocarcinoma (PDAC)2
  • Cancer2
  • Unresectable Locally Advanced1
  • Unresectable Locally Advanced or Metastatic Disease1
  • Metastatic Disease1

Other2 trials

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/2
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.